(1)All in constant currency, and in comparison to the nine months ended September 30, 2022 Q3 2023 Earnings Presentation November 2, 2023 Introducing Bruker Cellular Analysis, a Leader in Single-Cell Biology Tools Complements Bruker's spatial biology and single-cell research tools via acquisition of PhenomeX Beacon® Optofluidic Systems (former Berkeley Lights) IsoSpark® System (former IsoPlexis) Strategic Rationale ✓ Technologies unique, highly valued by customers ✓ Expands footprint in translational, clini ...

Financial Data and Key Metrics Changes - Bruker reported a revenue increase of 16.3% year-over-year for Q3 2023, reaching $742.8 million, with organic revenue growth of 10.9% [20][26][119] - Non-GAAP EPS for Q3 2023 was $0.74, up 12.1% from $0.66 in Q3 2022, with a favorable tax rate offsetting foreign exchange headwinds [12][111] - For the first nine months of 2023, revenues increased by 15.8% to $2.11 billion, with organic revenue growth of 13.9% [5][102] Business Line Data and Key Metrics Changes - The BioSpin segment saw high single-digit organic revenue growth in Q3 2023, with revenue of $541 million for the first nine months [11][112] - Bruker Nano revenue grew in the low-20s percentage range, driven by strong performance in industrial semiconductor metrology and academic markets [113][101] - The CALID Group had revenue of $703 million for the first nine months, with growth in the high-teens percentage, particularly in life science mass spectrometry [96][101] Market Data and Key Metrics Changes - Americas revenue grew in the low single-digit percentage, while Asia-Pacific revenue grew in the teens percentage range, and European revenue had low-teens percentage growth year-over-year [27] - The EMEA region experienced mid-20% revenue growth year-over-year in Q3 2023 [27] - The backlog at the end of Q3 2023 remains strong, with expectations of continued elevated levels into 2024 [50][106] Company Strategy and Development Direction - Bruker is focused on its Project Accelerate 2.0 initiative, which aims to enhance innovation and operational excellence [4][94] - The acquisition of PhenomeX is expected to expand Bruker's capabilities in single-cell biology and complement existing product lines [8][24] - The company anticipates solid organic growth in 2024 and reaffirms its medium-term targets for 2026 [120] Management's Comments on Operating Environment and Future Outlook - Management acknowledged demand weakness in certain areas, such as COVID testing and biopharma, but remains optimistic about growth in scientific instruments and life science solutions [4][54] - The company expects to maintain a book-to-bill ratio around 1 for the year, despite some weakness in China and Japan [50][122] - Management confirmed that while there are challenges in the biopharma sector, Bruker's diversified portfolio positions it well for continued growth [54][55] Other Important Information - Bruker generated $144.6 million of operating cash flow in the first nine months of 2023, up about $42 million from the previous year [28] - The company expects non-GAAP EPS for fiscal year 2023 to be in the range of $2.48 to $2.53, reflecting a slight dilution from the Cellular Analysis business [29][44] Q&A Session Summary Question: What is the outlook for backlog and its impact on growth? - Management indicated that backlog remains elevated and will contribute to organic growth over the medium term, with expectations of a multi-year story [57][106] Question: How is the integration of PhenomeX progressing? - The integration is being accelerated, focusing on optimizing costs and streamlining operations, with significant annualized cost reductions expected [66][78] Question: What are the dynamics in the biopharma market? - Management confirmed a slowdown in biopharma investments, particularly among emerging companies, but noted that Bruker has a diversified portfolio to mitigate risks [54][55] Question: How is pricing sensitivity affecting orders? - Management stated that pricing power remains solid, with no significant changes in customer behavior regarding price sensitivity observed [70][72] Question: What is the expected impact of the new product launches on sales? - The introduction of new products like the timsTOF Ultra is expected to enhance competitiveness, although there may be short-term reevaluation by customers [88][120]

Bruker Corporation (NASDAQ:BRKR) Morgan Stanley 21st Annual Global Healthcare Conference Call September 13, 2023 4:14 PM ET Company Participants Gerald Herman - Executive Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant All right. Good afternoon, everyone. I’m Tejas Savant, and I’m the life sciences analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at mo ...

[Part I FINANCIAL INFORMATION](index=3&type=section&id=Part%20I%20FINANCIAL%20INFORMATION) [Item 1: Unaudited Condensed Consolidated Financial Statements](index=3&type=section&id=Item%201%3A%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section presents Bruker Corporation's core unaudited financial statements for the period ended June 30, 2023, including balance sheets, income statements, and cash flows, with detailed notes on accounting policies, segment performance, acquisitions, and debt [Unaudited Condensed Consolidated Financial Statements](index=3&type=section&id=Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This subsection contains the primary financial tables, showing total assets increased to $3.86 billion, Q2 revenue rose 15.9% to $681.9 million, and H1 operating cash flow reached $100.5 million Condensed Consolidated Balance Sheet Data (in millions) | Account | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Total Current Assets** | $2,183.3 | $2,113.2 | | **Total Assets** | $3,857.0 | $3,611.8 | | **Total Current Liabilities** | $1,050.9 | $914.3 | | **Total Liabilities** | $2,594.4 | $2,480.0 | | **Total Shareholders' Equity** | $1,250.7 | $1,125.7 | Condensed Consolidated Income Statement Data (in millions, except per share data) | Metric | Q2 2023 | Q2 2022 | H1 2023 | H1 2022 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | $681.9 | $588.4 | $1,367.2 | $1,183.4 | | **Gross Profit** | $340.5 | $298.2 | $700.2 | $604.5 | | **Operating Income** | $86.2 | $73.9 | $208.9 | $170.4 | | **Net Income Attributable to Bruker** | $57.1 | $49.5 | $133.6 | $111.1 | | **Diluted EPS** | $0.39 | $0.33 | $0.91 | $0.74 | Condensed Consolidated Cash Flow Data - Six Months Ended June 30 (in millions) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $100.5 | $33.4 | | **Net cash used in investing activities** | $(134.2) | $(44.7) | | **Net cash used in financing activities** | $(41.0) | $(297.2) | [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations for the financial statements, covering revenue breakdowns, recent acquisitions, debt obligations, hedging activities, and segment-level operating income to clarify accounting treatments and underlying business events Revenue by Reportable Segment (in millions) | Segment | Q2 2023 | Q2 2022 | H1 2023 | H1 2022 | | :--- | :--- | :--- | :--- | :--- | | BSI BioSpin | $162.0 | $159.8 | $342.3 | $317.6 | | BSI CALID | $227.2 | $190.3 | $463.9 | $393.5 | | BSI NANO | $225.1 | $182.2 | $434.7 | $360.7 | | BEST | $72.7 | $59.2 | $134.9 | $118.9 | | **Total Revenue** | **$681.9** | **$588.4** | **$1,367.2** | **$1,183.4** | - In Q1 2023, the company acquired **97.15%** of Biognosys, AG, a proteomics contract research firm, for approximately **$80.1 million**[79](index=79&type=chunk)[104](index=104&type=chunk) - In Q2 2023, it acquired **60%** of Zontal Companies, a data management software provider, for approximately **$14.8 million**[79](index=79&type=chunk)[104](index=104&type=chunk) Operating Income by Reportable Segment (in millions) | Segment | Q2 2023 | Q2 2022 | H1 2023 | H1 2022 | | :--- | :--- | :--- | :--- | :--- | | BSI BioSpin | $23.8 | $28.0 | $71.2 | $65.8 | | BSI CALID | $44.0 | $42.2 | $101.6 | $90.3 | | BSI NANO | $31.3 | $14.6 | $60.7 | $36.9 | | BEST | $11.1 | $6.6 | $19.1 | $13.2 | | **Total Operating Income** | **$86.2** | **$73.9** | **$208.9** | **$170.4** | - Total debt outstanding was **$1.24 billion** as of June 30, 2023, an increase from **$1.22 billion** at year-end 2022[115](index=115&type=chunk) [Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=30&type=section&id=Item%202%3A%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes the company's Q2 and H1 2023 financial performance, highlighting strong revenue growth driven by demand, gross margin pressure from product mix and inflation, and discussions on operational results, liquidity, and capital resources [Overview](index=31&type=section&id=Overview) This subsection summarizes financial results, noting Q2 2023 revenue growth of **15.9%** to **$681.9 million**, H1 2023 revenue growth of **15.5%** to **$1.37 billion**, increased diluted EPS, and improved free cash flow to **$52.0 million** for H1 2023 Q2 2023 vs Q2 2022 Revenue Performance (in millions) | Metric | Q2 2023 | Q2 2022 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | $681.9 | $588.4 | $93.5 | 15.9% | | *Favorable FX Impact* | | | $2.8 | | | *Acquisition Impact* | | | $11.0 | | | *Organic Revenue Increase* | | | $79.7 | | H1 2023 vs H1 2022 Revenue Performance (in millions) | Metric | H1 2023 | H1 2022 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | $1,367.2 | $1,183.4 | $183.8 | 15.5% | | *Unfavorable FX Impact* | | | $(24.3) | | | *Acquisition Impact* | | | $23.7 | | | *Organic Revenue Increase* | | | $184.4 | | - Gross profit margin decreased to **49.9%** in Q2 2023 from **50.7%** in Q2 2022, due to unfavorable foreign exchange, acquisition costs, inflation, and product mix[36](index=36&type=chunk) Diluted Earnings Per Share (EPS) | Period | 2023 | 2022 | Change | | :--- | :--- | :--- | :--- | | **Q2** | $0.39 | $0.33 | +$0.06 | | **H1** | $0.91 | $0.74 | +$0.17 | [Results of Operations](index=35&type=section&id=Results%20of%20Operations) This subsection details operational performance for Q2 and H1 2023, showing revenue growth across all segments, a **16.6%** increase in Q2 operating income, and varying operating margin trends influenced by mix and inflation - In Q2 2023, revenue growth was strong across all segments: BSI CALID (**+19.4%**), BSI NANO (**+23.5%**), and BEST (**+22.8%**), driven by high demand for differentiated instruments and solutions[215](index=215&type=chunk) - R&D expenses increased to **10.4%** of revenue in Q2 2023 (from **10.1%** in Q2 2022) and **10.2%** in H1 2023 (from **9.8%** in H1 2022) due to increased investment in key 'Project Accelerate 2.0' initiatives[216](index=216&type=chunk)[206](index=206&type=chunk) - Interest and other expense, net, increased significantly, primarily due to impairment charges on strategic investments (**$11.4M** in Q2, **$18.3M** in H1) and higher foreign currency exchange losses[220](index=220&type=chunk)[209](index=209&type=chunk) - The effective tax rate decreased to **25.7%** in Q2 2023 (from **28.6%**) and **27.1%** in H1 2023 (from **31.7%**), mainly due to favorable impacts from U.S tax legislation and changes in jurisdictional mix[185](index=185&type=chunk)[233](index=233&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) This subsection outlines the company's financial position and cash management, with cash and equivalents at **$574.8 million**, operating cash flow for H1 2023 at **$100.5 million**, and a new **$500 million** share repurchase program authorized in May 2023 - Cash, cash equivalents, and short-term investments totaled **$574.8 million** at June 30, 2023, of which **$421.1 million** was held by foreign subsidiaries[213](index=213&type=chunk) - Net cash from operating activities increased to **$100.5 million** in H1 2023 from **$33.4 million** in H1 2022, primarily due to higher net income and favorable changes in operating assets and liabilities[240](index=240&type=chunk) - The 2021 share repurchase program expired in May 2023[241](index=241&type=chunk) - A new **$500 million**, two-year program was approved in May 2023, with no shares repurchased under it as of quarter-end[241](index=241&type=chunk)[251](index=251&type=chunk) Total Debt Outstanding (in millions) | Component | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Total notes and loans outstanding | $1,223.3 | $1,205.1 | | Finance lease obligations | $20.1 | $14.1 | | **Total debt** | **$1,243.4** | **$1,219.2** | [Item 3: Quantitative and Qualitative Disclosures About Market Risk](index=47&type=section&id=Item%203%3A%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section discusses the company's exposure to foreign currency, interest rate, commodity price, and inflation risks, detailing how derivatives are used to mitigate currency and interest rate volatility, and acknowledging inflationary pressures on global operations - A substantial portion of revenue is generated in international markets, exposing the company to foreign currency fluctuations[263](index=263&type=chunk) - For Q2 2023, currency translation rates had a positive **0.5%** impact on revenue, compared to a negative **7.3%** impact in Q2 2022[263](index=263&type=chunk)[265](index=265&type=chunk) - The company uses cross-currency and interest rate swaps to hedge its net investment in foreign operations and manage interest rate risk[258](index=258&type=chunk) - As of June 30, 2023, these swaps had notional values of **$142.9 million** (USD/CHF) and **$242.9 million** (USD/EUR)[258](index=258&type=chunk) - The company is exposed to commodity price risk for raw materials like copper and niobium-tin used in superconductors[269](index=269&type=chunk)[281](index=281&type=chunk) - It uses fixed-price commodity contracts to manage this volatility[269](index=269&type=chunk)[281](index=281&type=chunk) - The company is subject to inflationary cost pressures across its global supply chain, which has impacted and may continue to impact its cost of operations[270](index=270&type=chunk) [Item 4: Controls and Procedures](index=49&type=section&id=Item%204%3A%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of June 30, 2023, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of June 30, 2023[288](index=288&type=chunk) - There were no changes in internal control over financial reporting during the quarter ended June 30, 2023, that have materially affected, or are reasonably likely to materially affect, internal controls[274](index=274&type=chunk) [Part II OTHER INFORMATION](index=50&type=section&id=Part%20II%20OTHER%20INFORMATION) [Item 1: Legal Proceedings](index=50&type=section&id=Item%201%3A%20Legal%20Proceedings) The company is involved in ordinary course lawsuits and claims, none of which are expected to have a material impact, with an update provided on an ongoing patent dispute with Carl Zeiss Microscopy - The company states that no pending legal matters are reasonably likely to have a material impact on its business or financial statements[289](index=289&type=chunk) - A patent dispute with Carl Zeiss AG is ongoing, with a European patent application still pending at the EPO, though a related German infringement action was terminated[289](index=289&type=chunk) [Item 1A: Risk Factors](index=50&type=section&id=Item%201A%3A%20Risk%20Factors) This section directs investors to the detailed discussion of risk factors in the company's Annual Report on Form 10-K for the year ended December 31, 2022, for a comprehensive understanding of potential risks affecting the business - The report refers readers to the risk factors section of the Annual Report on Form 10-K for the year ended December 31, 2022[286](index=286&type=chunk) [Item 2: Unregistered Sales of Equity Securities and Use of Proceeds](index=50&type=section&id=Item%202%3A%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section discloses that the company did not purchase any common stock during Q2 2023, and no directors or officers adopted or terminated a Rule 10b5-1 trading plan during the quarter - The company did not make any purchases of its common stock during the quarter ended June 30, 2023, under its new **$500 million** share repurchase program announced in May 2023[291](index=291&type=chunk) - No directors or officers reported the adoption or termination of a Rule 10b5-1 trading arrangement during the quarter[287](index=287&type=chunk) [Item 5: Other Information](index=50&type=section&id=Item%205%3A%20Other%20Information) There was no other information required to be disclosed under this item for the reporting period - No information was reported under this item[292](index=292&type=chunk) [Item 6: Exhibits](index=51&type=section&id=Item%206%3A%20Exhibits) This section lists all exhibits filed with the Quarterly Report on Form 10-Q, including CEO and CFO certifications required by the Sarbanes-Oxley Act and Inline XBRL documents for financial data tagging - The exhibits filed with the report include CEO and CFO certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act, as well as Inline XBRL files[298](index=298&type=chunk)

Bruker Corporation (NASDAQ:BRKR) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Justin Ward - Senior Director of IR & Corporate Development Frank H. Laukien - Chairman, President & CEO Gerald N. Herman - EVP & CFO Conference Call Participants Puneet Souda - Leerink Partners Michael Ryskin - Bank of America Joshua Waldman - Cleveland Research Daniel Arias - Stifel, Nicolaus & Company Patrick Donnelly - Citigroup Daniel Brennan - TD Cowen Rachel Vatnsdal - J.P. Morgan Jack Mee ...

Bruker Corporation Investor Day Summary Company Overview - **Company**: Bruker Corporation (NASDAQ: BRKR) - **Date of Call**: June 15, 2023 - **Participants**: - Frank Laukien - Chairman, President and CEO - Rohan Thakur - President, Life Sciences Mass Spectrometry Division - Oliver Rinner - CEO of Biognosys Key Industry and Company Insights Strategic Focus - Bruker is focusing on **Proteomics** and **Spatial Biology** as key growth areas, supported by their **Project Accelerate 2.0** initiatives [6][10] - The company aims to outgrow the market growth rate of **4% to 6%** by **200 to 300 basis points** per year, with a revenue growth guidance midpoint of **10%** for the current year [6][7] Financial Performance - Bruker has transitioned from a market growth company to one that significantly outgrows market rates, achieving **19% growth** two years ago, partly due to recovery from COVID-19 [7][8] - The company expects to maintain a **low 20% operating margin** and deliver **double-digit non-GAAP EPS growth** despite a **10% R&D investment** [8][9] Market Trends and Innovations - Bruker is capitalizing on large secular trends in **proteomics**, **lipidomics**, and **spatial biology**, with significant investments in R&D [10][12] - The **timsTOF** platform is highlighted as a revolutionary tool in proteomics, enabling faster and more comprehensive analyses [38][49] - The company is also involved in **clean tech** and **renewable energy**, particularly in battery technology and superconducting technologies [13][26] Product Development and Acquisitions - Bruker has made significant advancements in mass spectrometry, particularly with the **timsTOF Ultra** and its capabilities in **4D-proteomics** [35][49] - The acquisition of **Biognosys** enhances Bruker's capabilities in proteomics, providing advanced tools and services for drug discovery and development [52][60] Customer Base and Market Segmentation - The customer base includes **biopharma**, **academic institutions**, and **core facilities**, with a focus on providing comprehensive solutions for proteomics needs [58][59] - Bruker has seen exceptional growth in the **United States**, particularly in biopharma and academic medical research, with the Americas now accounting for **30%** of revenue [16] Cultural and Operational Excellence - The company emphasizes a culture of **customer success**, **integrity**, and **quality**, which is integral to its operational excellence and growth strategy [17][18] - Bruker’s management process is described as **disciplined entrepreneurialism**, which differentiates it from competitors [9][19] Additional Important Insights - The **MALDI BioTyper** is recognized as a leader in applied clinical proteomics, with over **5,500 systems** installed globally [51][23] - Bruker is actively pursuing advancements in **AI** and **machine learning** to enhance data analysis and proteomics applications [28][40] - The company is committed to continuous innovation, with a focus on improving sample throughput and reducing sample amounts required for analysis [50][39] Conclusion Bruker Corporation is strategically positioned to leverage its strengths in proteomics and spatial biology, supported by robust financial performance and a commitment to innovation. The integration of Biognosys further enhances its capabilities in the life sciences sector, positioning Bruker as a leader in the evolving landscape of proteomics and related technologies.

On a quarterly basis, the Company reviews minority investments and equity method investments to determine if there have been any events and conditions that could indicate an impairment or other-than temporary impairment. In the three months ended March 31, 2023, the Company recognized $6.9 million of impairment charge in "Interest and other income (expense), net" in the Consolidated Statement of Operations, to write-off the costs of certain minority investments. No impairments were noted in the three months ...

Financial Data and Key Metrics Changes - Bruker reported a revenue increase of 15.2% year-over-year to approximately $685.3 million in Q1 2023, with organic revenue growth of 17.6% [13][20][26] - Non-GAAP gross margin increased by 70 basis points to 53.4%, while non-GAAP operating margin rose by 80 basis points to 20.3% [5][22][50] - Non-GAAP EPS for Q1 2023 was $0.64, reflecting a 30.6% increase from $0.49 in Q1 2022 [24][40][48] Business Line Data and Key Metrics Changes - The BioSpin Group revenue reached $180 million, growing in the high-teens percentage on a constant currency basis, driven by strong performance in NMR and MRI preclinical imaging [6][13] - The CALID Group revenue was $237 million, increasing in the low 20s percentage on a constant currency basis, with strong growth in life science mass spectrometry and vibrational spectroscopy [15][20] - NANO's revenue was $210 million, growing in the low 20% range, supported by strong demand in academic, industrial, and GreenTech research [42] Market Data and Key Metrics Changes - In the Americas and European markets, BSI revenues grew in the low-double-digits, while Asia-Pacific revenue increased by over 30% year-over-year [49] - The Rest of World revenue declined slightly in Q1 2023 [49] Company Strategy and Development Direction - Bruker is advancing its Project Accelerate 2.0, focusing on high-growth, high-margin initiatives, particularly in proteomics and spatial biology [4][19][46] - The company plans to ramp investments in proteomics, spatial biology, biopharma, and semiconductor metrology to drive future growth [46][82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for differentiated instruments and solutions, with a robust backlog providing good visibility for future growth [39][46] - The company raised its revenue guidance for the full year 2023 to a range of $2.83 billion to $2.88 billion, implying organic revenue growth of 9% to 11% year-over-year [52][53] Other Important Information - Bruker repurchased approximately 315,000 shares for about $22 million in Q1 2023, contributing positively to EPS [21][24] - The company expects a sequential decline in operating margin in Q2 2023, followed by recovery in the second half of the year [23][50] Q&A Session Summary Question: Could you elaborate on your approach to the updated organic growth guidance for '23? - Management indicated that they are exercising prudence in their guidance, considering the sequentially weaker Q2 [28][29] Question: Can you provide an update on the status of the loan program in China? - Management noted strong orders from China in Q1, primarily in high-end instrumentation, but indicated uncertainty about the continuation of the loan program [57][60] Question: What does the book-to-bill ratio look like for the quarter? - The book-to-bill ratio was slightly above 1, indicating strong order growth despite significant revenue growth [75] Question: How much of the first quarter strength was from order slippage from Q4 to Q1? - Management acknowledged some conservatism in guidance and noted that the exact impact of order slippage is still uncertain [136] Question: Can you provide more color on the growth in China during this quarter? - Management confirmed that while orders were strong, the conversion of those orders into revenue was limited due to backlog lead times [125][126]

Bruker Corporation (NASDAQ:BRKR) Cowen 43rd Annual Health Care Conference March 6, 2023 2:10 PM ET Company Participants Gerald Herman - EVP & CFO Conference Call Participants Max Masucci - Cowen & Co. Max Masucci Well again, welcome to TD Cowen's 43rd Annual Health Care Conference. I'm Max Masucci, one of the Life Science and Diagnostic Tools analysts here. We are pleased to be joined today by Bruker, one of the three large cap names in our coverage. And a diversified participant in several of the tools, di ...

Bruker Corporation (NASDAQ:BRKR) 2023 Citi Healthcare Services, Medtech, Tools & HCIT Conference March 2, 2023 9:30 AM ET Company Participants Gerald Herman - EVP & CFO Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly All right. We can look to get started. Thanks, everyone for being here. I'm Patrick Donnelly, the Tools and Diagnostics analyst here at Citi. Happy to have Gerald Herman, CFO of Bruker with us for this session. Gerald Herman Hello. Patrick Donnelly Gerald, thanks for bei ...